Advances in clinical chemistry最新文献_第4页

Metabolomics of heavy metal exposure. 重金属暴露的代谢组学。

Advances in clinical chemistry Pub Date : 2025-01-01 Epub Date: 2025-07-14 DOI: 10.1016/bs.acc.2025.06.005

Shagufta Kamal, Sumble Malik, Farwa Batool, Kanwal Rehman, Muhammad Sajid Hamid Akash

{"title":"Metabolomics of heavy metal exposure.","authors":"Shagufta Kamal, Sumble Malik, Farwa Batool, Kanwal Rehman, Muhammad Sajid Hamid Akash","doi":"10.1016/bs.acc.2025.06.005","DOIUrl":"https://doi.org/10.1016/bs.acc.2025.06.005","url":null,"abstract":"Heavy metal toxicity poses significant risks to environmental and human health, necessitating advanced analytical and integrative approaches for assessment and mitigation. Herein we review the use of high-resolution metabolomics, ultra-high-performance liquid chromatography-mass spectrometry (UHPLC-MS), and Fourier transform ion cyclotron resonance mass spectrometry (FT-ICR-MS) to identify metabolic disruptions associated with heavy metal exposure. NMR, due to a non-destructive nature and ability to provide quantitative and structural information, has emerged as a vital tool in identifying biomarkers and elucidating metabolic disruptions caused by heavy metals. Integrating genomics, transcriptomics, proteomics, and lipidomics with metabolomics has significantly enhanced the understanding of gene-environment interactions. Systems biology and computational modeling bridge experimental data with predictive insights, simulating complex interactions and identifying intervention points. Furthermore, this chapter explores advanced instrumentation and the role of interdisciplinary collaboration as metabolomics, enriched by NMR and multi-omics integration, holds the potential to manage the heavy metal toxicity, paving the way for precision medicine and environmental resilience.","PeriodicalId":101297,"journal":{"name":"Advances in clinical chemistry","volume":"128 ","pages":"109-154"},"PeriodicalIF":0.0,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144985213","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

MicroRNAs in metabolic syndrome: Mechanisms, diagnosis, and therapy. 代谢综合征中的microrna：机制、诊断和治疗。

Advances in clinical chemistry Pub Date : 2025-01-01 Epub Date: 2025-07-22 DOI: 10.1016/bs.acc.2025.06.003

Md Abdur Rahman, Md Mahmodul Islam, Md Monirul Islam, Md Abdur Rahman Ripon, Mohammad Salim Hossain

{"title":"MicroRNAs in metabolic syndrome: Mechanisms, diagnosis, and therapy.","authors":"Md Abdur Rahman, Md Mahmodul Islam, Md Monirul Islam, Md Abdur Rahman Ripon, Mohammad Salim Hossain","doi":"10.1016/bs.acc.2025.06.003","DOIUrl":"10.1016/bs.acc.2025.06.003","url":null,"abstract":"Metabolic syndrome is a group of cardio-metabolic dysfunctions characterized by increased fasting blood glucose, blood pressure, waist circumference, triglycerides, and decreased high-density lipoprotein cholesterol. Globally, the prevalence of metabolic syndrome ranged from 12.5-31.4 %, among which 5-7 % were young adults. Environmental factors, nutrition, and genetic and epigenetic predispositions are thought to interact intricately to cause metabolic disease. MicroRNAs are short, small non-coding RNAs that attach to the target coding sequences and untranslated genomic regions in many cell types, thereby post-transcriptionally suppressing gene expression. The human genome contains around 2000 microRNAs many of which appear linked to a numerous biologic and pathophysiologic processes, such as inflammatory response, angiogenesis, and glucose homeostasis. Many human disorders, including obesity, type 2 diabetes mellitus, and cardiovascular disorders, have been linked to deregulated microRNA expression. More recently, the identification of extracellular microRNAs has highlighted their potential as markers of disease and endocrine signaling molecules. This review provides an overview of microRNA biogenesis and its function in insulin signaling, adipogenesis, biology of pancreatic β-cell, and metabolism. We review current research on microRNAs linked to vascular diabetic complications and metabolic diseases, with a focus on their diagnostic and therapeutic potential.","PeriodicalId":101297,"journal":{"name":"Advances in clinical chemistry","volume":"128 ","pages":"181-247"},"PeriodicalIF":0.0,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144985133","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Advances in optical biosensors: Technologies and trends in point of care applications. 光学生物传感器的进展：护理点应用的技术和趋势。

Advances in clinical chemistry Pub Date : 2025-01-01 Epub Date: 2025-07-23 DOI: 10.1016/bs.acc.2025.07.001

Alper Baran Sözmen, Ayşe Ezgi Bayraktar, Özgür Ülker, Ahu Arslan-Yildiz

{"title":"Advances in optical biosensors: Technologies and trends in point of care applications.","authors":"Alper Baran Sözmen, Ayşe Ezgi Bayraktar, Özgür Ülker, Ahu Arslan-Yildiz","doi":"10.1016/bs.acc.2025.07.001","DOIUrl":"https://doi.org/10.1016/bs.acc.2025.07.001","url":null,"abstract":"A sensor detects changes in its environment and converts them into readable data using three key components: a receptor to sense changes, a transducer to generate a signal, and a detection system to output the signal. Optical sensors are devices that use a receptor and optical transducer to produce signals corresponding to an analyte, and optical biosensors combine a biological sensing element with an optical transducer to detect and quantify specific analytes. They offer easy-to-read, real-time signals, such as color changes or light emission, sometimes even detectable by the naked eye, reducing the need for external devices and providing versatile Point-of-Care (PoC) applicability. Their portability and rapid response time enable remote testing and monitoring, further improving accessibility. They allow sensitive and selective detection of various analytes, making them utile in areas like glucose monitoring, drug testing, and pathogen detection. Many of these sensors provide label-free and non-invasive detection, further enhancing patient comfort and safety. This chapter provides an overview of optical biosensors; it starts with categorizing them by biorecognition elements, transducers, and detection modes. It investigates biosensors that utilize nanomaterials, polymers, and engineered biorecognition elements are discussed, with examples from literature. Technologies such as miniaturization, multiplexing, and wearable designs, which enhance PoC feasibility, are also examined. Lastly, challenges in development and operation are addressed, and future research directions for advancing optical biosensors in PoC diagnostics are discussed.","PeriodicalId":101297,"journal":{"name":"Advances in clinical chemistry","volume":"129 ","pages":"1-52"},"PeriodicalIF":0.0,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145208886","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Emerging biomarkers in type 2 diabetes mellitus. 2 型糖尿病的新兴生物标志物。

Advances in clinical chemistry Pub Date : 2025-01-01 Epub Date: 2025-03-01 DOI: 10.1016/bs.acc.2025.01.002

Mohammad Muzaffar Mir, Mushabab Alghamdi, Waad Fuad BinAfif, Muffarah Hamid Alharthi, Abdullah M Alshahrani, Mohannad Mohammad S Alamri, Jaber Alfaifi, Ahmed Yahia Al Ameer, Rashid Mir

{"title":"Emerging biomarkers in type 2 diabetes mellitus.","authors":"Mohammad Muzaffar Mir, Mushabab Alghamdi, Waad Fuad BinAfif, Muffarah Hamid Alharthi, Abdullah M Alshahrani, Mohannad Mohammad S Alamri, Jaber Alfaifi, Ahmed Yahia Al Ameer, Rashid Mir","doi":"10.1016/bs.acc.2025.01.002","DOIUrl":"10.1016/bs.acc.2025.01.002","url":null,"abstract":"Diabetes mellitus is a chronic condition caused by high blood glucose resulting from insufficient insulin production or cellular resistance to insulin action or both. It is one of the fastest-growing public health concerns worldwide. Development of long-term nephropathy, retinopathy, neuropathy, and cardiovascular disease are some of the complications commonly associated with poor blood glycemic control. Type 2 diabetes mellitus (T2DM), the most prevalent type of diabetes, accounts for around 95 % of all cases globally. Although middle-aged or older adults are more likely to develop T2DM, its prevalence has grown in children and young people due to increased obesity, sedentary lifestyle and poor nutrition. Furthermore, it is believed that more than 50 % of cases go undiagnosed annually. Routine screening is essential to ensure early detection and reduce risk of life-threatening complications. Herein, we review traditional biomarkers and highlight the ongoing pursuit of novel and efficacious biomarkers driven by the objective of achieving early, precise and prompt diagnoses. It is widely acknowledged that individual biomarkers will inevitably have certain limitations necessitating the need for integrating multiple markers in screening.","PeriodicalId":101297,"journal":{"name":"Advances in clinical chemistry","volume":"126 ","pages":"155-198"},"PeriodicalIF":0.0,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143789498","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Advances in periodontal healing biomarkers. 牙周愈合生物标志物研究进展。

Advances in clinical chemistry Pub Date : 2025-01-01 Epub Date: 2025-01-30 DOI: 10.1016/bs.acc.2024.11.007

Ulvi Kahraman Gürsoy, Ilias Oikonomou, Mustafa Yilmaz, Mervi Gürsoy

{"title":"Advances in periodontal healing biomarkers.","authors":"Ulvi Kahraman Gürsoy, Ilias Oikonomou, Mustafa Yilmaz, Mervi Gürsoy","doi":"10.1016/bs.acc.2024.11.007","DOIUrl":"10.1016/bs.acc.2024.11.007","url":null,"abstract":"Periodontitis is the infectious-inflammatory disease of tooth-supporting tissues. Periodontal treatment, either non-surgical or surgical, aims to remove infection, reduce inflammation, eliminate tissue loss, and gain clinical attachment. Clinical and radiographic recordings are widely used and accepted as gold-standard methods in periodontal diagnostics. While these traditional methods allow clinicians to monitor and diagnose periodontitis, they cannot be used to estimate the course of periodontal healing, or predict the disease recurrence or estimate the treatment outcome. Early prediction of the long-term consequences of periodontal treatment would be a crucial and valuable information not only for the clinicians, but also for the patients. Rapid advancements during past few decades boosted the periodontal biomarker studies and various microbe- or host-derived biochemical markers have been suggested as diagnostic biomarkers of periodontitis. Yet, there is no consensus regarding the accuracy of diagnostic biomarkers to monitor treatment response or to predict prognosis. The aim of this chapter will be to describe the healing patterns of periodontal tissues after treatment and present the available evidence on biomarkers that can indicate or predict successful treatment outcomes.","PeriodicalId":101297,"journal":{"name":"Advances in clinical chemistry","volume":"125 ","pages":"143-167"},"PeriodicalIF":0.0,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143485251","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Urinary biomarkers of preeclampsia: An update. 子痫前期的尿液生物标志物：最新进展。

Advances in clinical chemistry Pub Date : 2025-01-01 Epub Date: 2024-11-22 DOI: 10.1016/bs.acc.2024.11.002

Caio Ribeiro Vieira Leal, Heloisa Botezelli, Júlia Fernandes do Carmo Las Casas, Ana Cristina Simões E Silva, Fernando M Reis

{"title":"Urinary biomarkers of preeclampsia: An update.","authors":"Caio Ribeiro Vieira Leal, Heloisa Botezelli, Júlia Fernandes do Carmo Las Casas, Ana Cristina Simões E Silva, Fernando M Reis","doi":"10.1016/bs.acc.2024.11.002","DOIUrl":"10.1016/bs.acc.2024.11.002","url":null,"abstract":"Preeclampsia (PE), a pregnancy-related syndrome, has motivated extensive research to understand its pathophysiology and develop early diagnostic methods. 'Omic' technologies, focusing on genes, mRNA, proteins, and metabolites, have revolutionized biological system studies. Urine emerges as an ideal non-invasive specimen for omics analysis, offering accessibility, easy collection, and stability, making it valuable for identifying biomarkers. A comprehensive exploration of urinary omics in preeclampsia is discussed in this review. Proteomic studies identified biomarkers such as SERPINA-1 and uromodulin, showing promise for early diagnosis and severity assessment. Metabolomic analyses revealed alterations in metabolites like glycine and hippurate, providing insights into molecular mechanisms underlying PE. Challenges include methodological inconsistencies and the need for standardized protocols. Urinary omics technologies have significantly advanced our understanding of PE pathophysiology and hold promise for improved diagnosis and management. Biomarkers identified through these approaches offer potential for early detection, severity stratification, and elucidation of underlying mechanisms.","PeriodicalId":101297,"journal":{"name":"Advances in clinical chemistry","volume":"124 ","pages":"197-211"},"PeriodicalIF":0.0,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143019638","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Multiomics in cancer biomarker discovery and cancer subtyping. 多组学在癌症生物标志物发现和癌症分型中的应用。

Advances in clinical chemistry Pub Date : 2025-01-01 Epub Date: 2024-10-29 DOI: 10.1016/bs.acc.2024.10.004

Seunghwan Choi, Joon-Yong An

{"title":"Multiomics in cancer biomarker discovery and cancer subtyping.","authors":"Seunghwan Choi, Joon-Yong An","doi":"10.1016/bs.acc.2024.10.004","DOIUrl":"10.1016/bs.acc.2024.10.004","url":null,"abstract":"The advent of multiomics has ushered in a new era of cancer research characterized by integrated genomic, transcriptomic and proteomic analysis to unravel the complexities of cancer biology and facilitate the discovery of novel biomarkers. This chapter provides a comprehensive overview of the concept of multiomics, detailing the significant advances in the underlying technologies and their contributions to our understanding of cancer. It delves into the evolution of genomics and transcriptomics, breakthroughs in proteomics, and overarching progress in multiomic methodologies, highlighting their collective impact on cancer biomarker discovery. Furthermore, this chapter explores the computational methods essential for multiomic studies, including clustering techniques for delineating cancer subtypes, strategies for estimating molecular features and activities, and utility of pathway enrichment analyses for interpreting multiomic datasets. Particular focus has been placed on the application of these methods for identifying distinct cancer subtypes, thereby enabling a more personalized approach to cancer treatment. Through a detailed discussion of the scientific principles, technological advancements, and practical applications of multiomics, this chapter aims to underscore the pivotal role of multiomics in advancing cancer research and paving the way for personalized medicine. The insights provided herein not only illuminate the current landscape of cancer biomarker discovery, but also forecast future directions of multiomics research in oncology, advocating for a more integrated and nuanced approach to understanding and combating cancer.","PeriodicalId":101297,"journal":{"name":"Advances in clinical chemistry","volume":"124 ","pages":"161-195"},"PeriodicalIF":0.0,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143019600","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Preface. 前言。

Advances in clinical chemistry Pub Date : 2025-01-01 DOI: 10.1016/S0065-2423(25)00090-3

Gregory S Makowski

引用次数: 0

Advances in blood microsampling technology for cancer biomarker detection. 血液微采样技术在癌症生物标志物检测中的应用进展。

Advances in clinical chemistry Pub Date : 2025-01-01 Epub Date: 2025-06-09 DOI: 10.1016/bs.acc.2025.04.005

Natasha Lucas, Ben R Herbert, Mark P Molloy

{"title":"Advances in blood microsampling technology for cancer biomarker detection.","authors":"Natasha Lucas, Ben R Herbert, Mark P Molloy","doi":"10.1016/bs.acc.2025.04.005","DOIUrl":"https://doi.org/10.1016/bs.acc.2025.04.005","url":null,"abstract":"Blood microsampling has demonstrated clinical utility for applications in the fields of newborn screening, therapeutic drug monitoring (TDM) of immunosuppressive drugs, and for viral detection. However, for cancer diagnostics, including early diagnosis, disease recurrence or TDM, use of blood microsampling technology is still in its infancy. Nonetheless, rapid innovation in microsampling device design coupled with proof of principle studies suggests high enthusiasm for the future integration of blood microsampling for clinical cancer applications. In this review we discuss the opportunities and challenges of using microsampling for biospecimen collection and analysis, including the stability of biomarkers using dried blood spots as this is crucial in applications relying on self-collected specimens. We highlight current research in the 'omics' biomarker field with respect to cancer diagnostics, covering applications of microsampling with proteomics, metabolomics, lipidomics, glycomics, genomics and epigenetics. Although the landscape of blood microsampling is still evolving, the potential of this technology to provide a promising solution to some of the challenges in biospecimen collection and cancer diagnostics makes it a rapidly developing and innovative research area.","PeriodicalId":101297,"journal":{"name":"Advances in clinical chemistry","volume":"127 ","pages":"173-219"},"PeriodicalIF":0.0,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144621664","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Preface. 前言。

Advances in clinical chemistry Pub Date : 2025-01-01 DOI: 10.1016/S0065-2423(25)00063-0

Gregory S Makowski

引用次数: 0